Quantum BioPharma submits IND application

Quantum BioPharma has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) for its Phase Two clinical trial of Lucid-MS. This trial will investigate the efficacy of Lucid-MS in treating Multiple Sclerosis. The submission marks a critical step forward in the drug development process, moving Quantum BioPharma closer to potential human testing and eventual market approval. This regulatory milestone signifies progress in the company's efforts to develop novel therapies for neurological conditions.